Accepted Manuscript



Reversed Isoniazids: Design, synthesis and evaluation against *Mycobacterium tuberculosis*

Malkeet Kumar, Kawaljit Singh, Andile H. Ngwane, Fahreta Hamzabegovic, Getahun Abate, Bienyameen Baker, Ian Wiid, Daniel F. Hoft, Peter Ruminski, Kelly Chibale

PII: S0968-0896(17)31809-6
DOI: https://doi.org/10.1016/j.bmc.2017.12.047
Reference: BMC 14152

To appear in: *Bioorganic & Medicinal Chemistry*

Received Date: 13 September 2017
Revised Date: 20 December 2017
Accepted Date: 28 December 2017

Please cite this article as: Kumar, M., Singh, K., Ngwane, A.H., Hamzabegovic, F., Abate, G., Baker, B., Wiid, I., Hoft, D.F., Ruminski, P., Chibale, K., Reversed Isoniazids: Design, synthesis and evaluation against *Mycobacterium tuberculosis*, *Bioorganic & Medicinal Chemistry* (2017), doi: https://doi.org/10.1016/j.bmc.2017.12.047

Reversed Isoniazids: Design, synthesis and evaluation against *Mycobacterium tuberculosis*

Malkeet Kumar[a], Kawaljit Singh[a], Andile H. Ngwane[b], Fahreta Hamzabegovic[c], Getahun Abate[c], Bienyameen Baker[b], Ian Wiid[b], Daniel F. Hoft[c,d], Peter Ruminski[f], Kelly Chibale[a,e,g]*

[a]Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

[b]DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town, 8000, South Africa.

[c]Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University, 1100 S. Grand Blvd, 63104, MO, USA

[d]Department of Molecular Biology, Saint Louis University, 1100 S. Grand Blvd, 63104, MO, USA

[e]Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.

[f]Centre for World Health and Medicine, Saint Louis University, 1100 S. Grand Blvd, 63104, MO, USA

[g]South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

Abstract:

Novel reversed isoniazid (RINH) agents have been synthesized by covalently linking isoniazid with various efflux pump inhibitors (EPIs) cores and their structural motifs. These RINH agents were evaluated for anti-mycobacterial activity against sensitive, isoniazid mono-resistant and MDR clinical isolates of *M. tuberculosis* and a selected number of compounds were also tested *ex vivo* for intracellular activity as well as in the ethidium